Publications by authors named "Udo Eichenlaub"

Claim this Profile
A
An accurate fully automated panel of plasma biomarkers for Alzheimer's disease.
Sebastian Palmqvist, Erik Stomrud, Nicholas Cullen, Shorena Janelidze, Ekaterina Manuilova, Udo Eichenlaub

Alzheimers Dement· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantifying the Vaccine-Induced Humoral Immune Response to Spike-Receptor Binding Domain as a Surrogate for Neutralization Testing Following mRNA-1273 (Spikevax) Vaccination Against COVID-19.
Imke Kirste, Sayuri Hortsch, Veit Peter Grunert, Holly Legault, Maha Maglinao, Udo Eichenlaub

Infect Dis Ther· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials.
Susanne Ostrowitzki, Tobias Bittner, Kaycee M Sink, Howard Mackey, Christina Rabe, Udo Eichenlaub

JAMA Neurol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of Alzheimer's disease amyloid beta 1-42, p-tau, and t-tau assays.
Argonde C van Harten, Heather J Wiste, Stephen D Weigand, Michelle M Mielke, Walter K Kremers, Udo Eichenlaub

Alzheimers Dement· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline.
Michelle M Mielke, Jeremiah A Aakre, Alicia Algeciras-Schimnich, Nicholas K Proctor, Mary M Machulda, Udo Eichenlaub

Alzheimers Dement· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort.
Michaela Amft, Marion Ortner, Udo Eichenlaub, Oliver Goldhardt, Janine Diehl-Schmid

Alzheimers Res Ther· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration.
Niklas Mattsson-Carlgren, Lea T Grinberg, Adam Boxer, Rik Ossenkoppele, Magnus Jonsson, Udo Eichenlaub

Neurology· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1 Trial.
Simon Jochum, Imke Kirste, Sayuri Hortsch, Veit Peter Grunert, Holly Legault, Udo Eichenlaub

Front Immunol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.
Shorena Janelidze, Charlotte E Teunissen, Henrik Zetterberg, José Antonio Allué, Leticia Sarasa, Udo Eichenlaub

JAMA Neurol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical utility of Elecsys Anti-SARS-CoV-2 S assay in COVID-19 vaccination: An exploratory analysis of the mRNA-1273 phase 1 trial.
Simon Jochum, Imke Kirste, Sayuri Hortsch, Veit Peter Grunert, Holly Legault, Udo Eichenlaub

medRxiv· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts.
Karine Provost, Leonardo Iaccarino, David N Soleimani-Meigooni, Suzanne Baker, Lauren Edwards, Udo Eichenlaub

Eur J Nucl Med Mol Imaging· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CSF biomarkers in Olmsted County: Evidence of 2 subclasses and associations with demographics.
Argonde C Van Harten, Heather J Wiste, Stephen D Weigand, Michelle M Mielke, Walter K Kremers, Udo Eichenlaub

Neurology· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia.
Shorena Janelidze, Niklas Mattsson, Sebastian Palmqvist, Ruben Smith, Thomas G Beach, Udo Eichenlaub

Nat Med· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease.
Sebastian Palmqvist, Philip S Insel, Erik Stomrud, Shorena Janelidze, Henrik Zetterberg, Udo Eichenlaub

EMBO Mol Med· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays.
Kaj Blennow, Leslie M Shaw, Erik Stomrud, Niklas Mattsson, Jon B Toledo, Udo Eichenlaub

Sci Rep· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status.
Sebastian Palmqvist, Shorena Janelidze, Erik Stomrud, Henrik Zetterberg, Johann Karl, Udo Eichenlaub

JAMA Neurol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.
Oskar Hansson, John Seibyl, Erik Stomrud, Henrik Zetterberg, John Q Trojanowski, Udo Eichenlaub

Alzheimers Dement· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Derivation of cutoffs for the Elecsys amyloid β (1-42) assay in Alzheimer's disease.
Leslie M Shaw, Teresa Waligorska, Leona Fields, Magdalena Korecka, Michal Figurski, Udo Eichenlaub

Alzheimers Dement (Amst)· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements.
Maria Bjerke, Ulf Andreasson, Julia Kuhlmann, Erik Portelius, Josef Pannee, Udo Eichenlaub

Clin Chem Lab Med· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1-42) in human cerebrospinal fluid.
Tobias Bittner, Henrik Zetterberg, Charlotte E Teunissen, Richard E Ostlund, Michael Militello, Udo Eichenlaub

Alzheimers Dement· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis